VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Petrylak on the Future Immunotherapy in Bladder Cancer

Daniel P. Petrylak, MD
Published: Wednesday, May 27, 2015



Daniel Petrylak, MD, Professor of Medicine and of Urology; Professor, Signal Transduction Research Program at Yale Cancer Center discusses the future of immunotherapy in bladder cancer.

There are several immunotherapies being investigated for bladder cancer. The FDA grated breakthrough status to the anti PDL-1 antibody last year. A confirmatory trial has been completed looking at second-line treatment for that therapy, says Peterlak.

A randomized trial of pemobrolizmab versus standard chemotherapy in patients with second-line bladder cancer is also currently underway. In second-line bladder cancer there will hopefully a drug approval in the next year for both of these agents, says Peterlak.

In the first-line setting, immunotherapies are needed for patients that are elderly, frail, or do not have the kidney function to undergo platinum-based therapy. This is being investigated in several phase trials .
 


Daniel Petrylak, MD, Professor of Medicine and of Urology; Professor, Signal Transduction Research Program at Yale Cancer Center discusses the future of immunotherapy in bladder cancer.

There are several immunotherapies being investigated for bladder cancer. The FDA grated breakthrough status to the anti PDL-1 antibody last year. A confirmatory trial has been completed looking at second-line treatment for that therapy, says Peterlak.

A randomized trial of pemobrolizmab versus standard chemotherapy in patients with second-line bladder cancer is also currently underway. In second-line bladder cancer there will hopefully a drug approval in the next year for both of these agents, says Peterlak.

In the first-line setting, immunotherapies are needed for patients that are elderly, frail, or do not have the kidney function to undergo platinum-based therapy. This is being investigated in several phase trials .
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x